Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular

This page shows the latest cardiovascular news and features for those working in and with pharma, biotech and healthcare.

Trial of Amgen, Servier’s heart failure drug clears interim check

Trial of Amgen, Servier’s heart failure drug clears interim check

AstraZeneca is waiting for regulatory verdicts on its SGLT2 inhibitor Farxiga (dapagliflozin) as a treatment to reduce the risk of cardiovascular death or the worsening of heart failure in adults with ... other cardiovascular risks last year.

Latest news

More from news
Approximately 43 fully matching, plus 910 partially matching documents found.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Big pharma and new start-ups. Arvinas recently attracted a $750m-plus partnership with Bayer to develop PROTAC drugs for cardiovascular and gynaecological diseases and cancer, as well as agricultural products,

  • The evolution of marketing – the Amgen way The evolution of marketing – the Amgen way

    Let’s take cardiovascular disease as an example. There has been incredible scientific progress. ... Can we accept a future where the impact of cardiovascular disease is the same as today?

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    This would create a similar situation to cardiovascular disease where we use cholesterol as a biomarker and give statins in a preventative mode. ... To advance Alzheimer’s research, I believe that there are similar lessons to learn from the advances in

  • The evolution of real-world studies The evolution of real-world studies

    The UK is an ideal setting for population-based studies of diabetes because diabetes care is largely coordinated by the GP, and information about metabolic parameters, cardiovascular risk factors, diabetes

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    CRISPR libraries aren’t exclusively reserved for oncology, however. AstraZeneca has confirmed that it is applying the tech across other therapy areas, including cardiovascular, renal, metabolism and respiratory, with the continued

More from intelligence
Approximately 0 fully matching, plus 73 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 55 partially matching documents found.

Latest from PMHub

  • Digital therapeutics and their impact on society

    This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.

  • Language barriers: Obesity has become a loaded word

    What’s the answer? It’s not an easy challenge. On the one hand, being obese does put you at higher risk of serious health conditions such as diabetes, cardiovascular disease

  • WHITE PAPER: Patient nonadherence – the $637bn paradox WHITE PAPER: Patient nonadherence – the $637bn paradox

    Adherence to drugs that prevent. cardiovascular disease: meta-analysis on 376, 162 patients. ... Better. compliance to antihypertensive medications reduces cardiovascular risk. J. Hypertens 2011; 29(3):610–618.

  • Wilmington Healthcare appoints new consultants

    Before joining Wilmington Healthcare, Sarah was National Policy and Partnership Lead for AstraZeneca UK’s cardiovascular and renal franchise, and provided strategic insight on NHS policies, commissioning and reimbursement pathways. ... Other posts that

  • What is changing in cardiovascular disease care?

    Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma. ... Introduction. Cardiovascular disease (CVD), which covers a wide range of conditions, such as

More from PMHub
Approximately 3 fully matching, plus 47 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics